Daewoong Pharma (069620) Stock Price & News

069620:KRX

Daewoong Pharma

₩108,300.00

+1.98%

(+2,100.00) 1D

Sep 28, 3:30:30 PM GMT+9 · KRW

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for 069620...

Open

₩106,900

High

₩109,050

Low

₩106,800

Mkt. cap

1.25T

Avg. vol.

21.95K

Volume

11.25K

Dividend

0.55%

Quarterly dividend

₩150

Ex-dividend date

Dec 27, 2023

P/E ratio

6.37

52-wk high

₩199,400

52-wk low

₩105,000

EPS

₩16,988

Shares outstanding

11.59M

No. of employees

Open

₩106,900

High

₩109,050

Low

₩106,800

Mkt. cap

1.25T

Avg. vol.

21.95K

Volume

11.25K

Dividend

0.55%

Quarterly dividend

₩150

Ex-dividend date

Dec 27, 2023

P/E ratio

6.37

52-wk high

₩199,400

52-wk low

₩105,000

EPS

₩16,988

Shares outstanding

11.59M

No. of employees

Related stocks

Profile

Daewoong Pharmaceutical Co., Ltd. is a pharmaceutical company headquartered in Seoul, South Korea. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products, including prescription and over-the-counter healthcare products. Wikipedia

About Daewoong Pharma

CEOChang-jae Lee | Seongsoo Park

Employees1.89K

Founded1945

Headquarters-

SectorPharmaceutical industry

Websitedaewoong.com

All values in KRW	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	411.83B	397.12B	377.80B	448.46B
Cost of goods sold	198.11B	185.96B	196.61B	199.39B
Cost of revenue	198.11B	185.96B	196.61B	199.39B
Research and development expenses	8.31B	139.98B	16.11B	14.81B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	144.21B	23.12B	136.65B	154.92B
Operating expense	156.83B	169.10B	158.98B	181.01B
Total operating expenses	354.94B	355.06B	355.59B	380.40B
Operating income	56.89B	42.06B	22.21B	68.07B
Other non operating income	-1.16B	2.77B	1.52B	-36.53B
EBT including unusual items	54.73B	68.97B	33.97B	21.89B
EBT excluding unusual items	54.73B	88.02B	11.82B	21.89B
Income tax expense	7.42B	-16.73B	8.46B	1.98B
Effective tax rate	13.56%	-24.26%	24.89%	9.02%
Other operating expenses	1.17B	1.17B	1.88B	1.61B
Net income	46.37B	89.84B	25.90B	33.37B
Net profit margin	11.26%	22.62%	6.86%	7.44%
Earnings per share	-	-	-	-
Interest and investment income	-	1.12B	1.74B	-
Interest expense	-	-3.53B	-8.00B	-
Net interest expenses	-	-2.41B	-6.26B	-
Depreciation and amortization charges	1.77B	1.43B	1.15B	7.94B
EBITDA	69.45B	56.04B	38.38B	92.95B
Gain or loss from assets sale	-12.80M	-52.31B	35.01M	-7.54M

Finance

Ask anything